- Home
- Knowledge centre
- Eye glossary A–Z
- Retinitis Pigmentosa: Inheritance, Genes, Symptoms and Treatment
Retinitis Pigmentosa: Inheritance, Genes, Symptoms and Treatment
Medically reviewed by {{surgeon}}, {{surgeon's title and specialty}}, on {{review date}}. Last updated {{date}}.
Retinitis pigmentosa (RP) (noun, abbreviated RP): retinitis pigmentosa is a group of inherited eye diseases in which the light-sensing cells of the retina slowly break down, usually starting with poor night vision and narrowing the side vision into "tunnel vision". Retinitis pigmentosa inheritance can be recessive, dominant or X-linked, and more than 100 genes are involved, although many patients are the first in their family to be diagnosed.
Retinitis pigmentosa: key facts
- What it is
- An inherited degeneration of the retina's rod and cone photoreceptor cells (it is not an infection, despite the "-itis" in the name)
- How common
- About 1 in 3,500 to 1 in 4,000 people in the United States and Europe; the most common inherited retinal disease
- First symptom
- Trouble seeing in dim light (night blindness), typically in childhood or adolescence
- Inheritance
- Autosomal recessive, autosomal dominant or X-linked; rarely digenic; many cases have no known family history
- Genes
- More than 100 genes; the best known are RHO (dominant), USH2A (recessive) and RPGR (X-linked)
- Cure
- None for most forms. One gene therapy (Luxturna) is FDA-approved for the rare RPE65 form
- What can be treated
- Cataract, swelling at the macula (cystoid macular oedema), and vision support with low-vision aids
- Specialist
- Retina specialist; at Laser Istanbul Clinic, Doç. Dr. Muhammet Derda Özer (Doç. = Associate Professor)
Retinitis pigmentosa inheritance: how is RP passed on?
Retinitis pigmentosa inheritance can follow three main patterns, and which one applies to a family decides the risk for children and relatives. The pattern is found through the family history and, increasingly, through genetic testing.
| Pattern | How it works | Risk to children (Foundation Fighting Blindness) | Typical features |
|---|---|---|---|
| Autosomal recessive | Both parents are healthy carriers of a changed gene; the child receives one copy from each | Each child of two carrier parents has a 25% chance of being affected | In one 2026 review, recessive forms were put at 50–60% of cases; onset is usually in the first decade |
| Autosomal dominant | One copy of the changed gene is enough; an affected parent passes it on | Each child of an affected parent has a 50% chance of being affected | Generally milder, and onset can be later (after age 50 in some families) |
| X-linked | The gene sits on the X chromosome; mothers usually carry it, sons are mainly affected | A carrier mother has a 50% chance of passing it to each child: affected sons, carrier daughters | The most severe form; starts early and often comes with short-sightedness |
Two more points families often ask about:
- Many patients have no relatives with RP. According to MedlinePlus Genetics, 40–50% of people with non-syndromic RP have no family history. This usually means two silent recessive carriers, or a new gene change; it does not mean the disease is "not genetic".
- Female carriers can be affected. In X-linked RP, MedlinePlus reports that at least 20% of women who carry one altered copy develop some vision loss, so a carrier mother should also have her eyes examined.
Which RP inheritance pattern is most common?
In most large studies, autosomal recessive RP is the most common pattern, followed by autosomal dominant, with X-linked RP the least common but the most severe. Exact percentages differ between populations, between clinics and between the studies that count patients versus genes, so no single figure fits every family. Be aware that some patient-information sites list dominant RP as the most frequent pattern; a genetic test on your own family is the only way to know your pattern.
Because the answer changes the risk for children, genetic counselling is advised for every family, ideally before having children and also when the disease looks "sporadic".
Retinitis pigmentosa genes: which genes cause RP?
More than 100 genes can cause retinitis pigmentosa. A 2026 analysis of gene discovery counted 105 genes linked to RP, of which about three-quarters follow a recessive pattern (77 of 105), 14 a dominant pattern, 5 an X-linked pattern and 9 more than one pattern.
- RHO (rhodopsin): the most frequent cause of dominant RP.
- USH2A: the most frequent recessive gene; changes in it can cause RP alone or Usher syndrome (RP with hearing loss).
- RPGR: the most frequent cause of X-linked RP.
- EYS: an important recessive gene, especially in East Asia but also found in European cohorts.
- RPE65: a rare cause, and the only one with an approved gene therapy so far.
About 20–30% of RP is syndromic, meaning it occurs together with problems elsewhere in the body; Usher syndrome (hearing loss) is the most common example. Anyone with RP and hearing difficulty should be assessed for it.
Genetic testing finds the causative gene in roughly 40–75% of people with an inherited retinal disease, so a negative result does not rule out RP. Knowing the gene matters for three reasons: it confirms the inheritance pattern, it shows which family members are at risk, and it decides whether you could be eligible for a gene-therapy trial or an approved treatment.
Retinitis pigmentosa symptoms: what does RP look like?
The usual order of symptoms is:
Night blindness
Difficulty moving around in dim light or adjusting when you go from light into the dark. It is often the first sign and is easy to dismiss as "poor night vision".
Loss of side vision
The visual field shrinks from the mid-periphery outwards. People bump into things, miss objects at the side or find crowded places difficult. In late stages only a small central "tunnel" remains.
Reduced central vision
Reading, recognising faces and colour vision can be affected as the disease reaches the macula.
Glare and light sensitivity
, and sometimes a hazy cataract that makes everything worse.
Other eye changes that doctors see include a clouded lens (posterior subcapsular cataract) and swelling at the macula (cystoid macular oedema), which affects about 30% of patients according to EyeWiki.
How fast does retinitis pigmentosa progress?
There is no single speed: RP progresses slowly in many people and faster in others, and it varies between families, genes and even between two relatives with the same gene change. As general guides:
- X-linked RP is usually the most severe and dominant RP generally the mildest.
- In an analysis cited by EyeWiki, central vision was well preserved in most younger patients: a central field radius of at least 10 degrees remained in 93% of those under 20, 89% of those aged 20–40 and 60% of those over 40.
- In a large study of about 1,000 patients aged 45 and over, a quarter had vision of 20/200 or worse in both eyes, over half kept 20/40 or better in at least one eye, and only 0.5% were completely blind in both eyes.
- The Foundation Fighting Blindness notes that many people with RP are legally blind by age 40, defined as a central visual field of less than 20 degrees; legal blindness does not mean no sight at all.
Rapid change, new central blur or distortion, or a sudden drop in vision should always be checked promptly, because cataract and macular swelling are treatable causes.
How is retinitis pigmentosa diagnosed?
Your eye doctor will usually combine several tests:
- Dilated retinal examination. The classic signs are dark, branching "bone-spicule" pigment deposits, thin retinal vessels and a pale optic disc.
- Visual field test. Maps how far your side vision reaches and tracks change over time.
- Electroretinogram (ERG). Measures the electrical response of the retina to light; in RP it is reduced or flat, often before the retina looks abnormal.
- Optical coherence tomography (OCT). A cross-section scan that shows the retinal layers and detects macular swelling.
- Genetic testing. Identifies the gene and the inheritance pattern.
Retina specialists also check for conditions that can mimic RP, including some inflammatory diseases. If you have been told you have RP and want a second opinion on the diagnosis, you can send your existing scans for review before travelling.
Is retinitis pigmentosa curable? Treatment in 2026
There is currently no cure for most forms of retinitis pigmentosa. Treatment aims to protect the sight you have, treat complications and help you live with low vision. What exists in 2026:
| Option | What it does | Who it is for |
|---|---|---|
| Gene therapy: voretigene neparvovec (Luxturna) | A working copy of the RPE65 gene is placed under the retina during a vitrectomy-type operation. FDA-approved on 19 December 2017 for "confirmed biallelic RPE65 mutation-associated retinal dystrophy" | Only people with two faulty copies of RPE65, confirmed by genetic testing. This is a small minority of RP |
| Cataract surgery | Removes a clouded lens that adds to blur and glare | RP patients with cataract |
| Treatment of macular swelling | Dorzolamide or brinzolamide drops, oral acetazolamide, or injections in selected cases | RP with cystoid macular oedema |
| Vitamin A and other supplements | Evidence is mixed: EyeWiki describes 15,000 IU/day of vitamin A palmitate (with lutein and oily fish) as slowing the decline of retinal function in adults, while the American Academy of Ophthalmology states vitamin A is not currently recommended because benefit is unclear and there are risks | Only on the advice of your retina specialist; vitamin A is unsuitable in pregnancy, kidney failure and with long-term doxycycline |
| Retinal implant (Argus II) | Gave light and dark perception in end-stage RP, but is no longer manufactured | Historical interest; not available as a new treatment |
| Low-vision rehabilitation | Magnifiers, lighting, mobility training and digital aids | Everyone with reduced vision |
Do not start high-dose vitamins on your own. Vitamin A in high doses can be harmful, and the benefit is debated.
Retinitis pigmentosa gene therapy: the state of play in 2026
Gene therapy is the area where the most is happening, and it is where the questions "how soon will there be a cure for retinitis pigmentosa?" and "is there an FDA-approved gene therapy?" are asked. In the sources we checked on 7 October 2026:
- Approved: Luxturna, for the RPE65 form only.
- In late-stage trials: gene-specific programmes for X-linked RP (RPGR), including a completed phase 3 trial (AAV5-RPGR, NCT04671433, finished September 2024) and a phase 2/3 trial of AGTC-501 (NCT04850118, primary completion date listed as June 2026); and a gene-agnostic phase 3 trial of OCU400 (NCT06388200, listed as active, not recruiting, with a completion date of February 2027).
- Optogenetics: MCO-010 has completed a phase 2 trial in adults with RP (NCT04945772, completed February 2023); this approach aims to make remaining retinal cells light-sensitive whatever the faulty gene.
- Early trials also include cell therapies and a USH1B gene therapy (phase 1/2).
Trials continue and results and approvals change quickly, so please treat this list as a snapshot and check ClinicalTrials.gov or ask your retina specialist for the current position. Nobody can say when, or for which forms, a broadly effective treatment will arrive, and anyone who promises a cure date is guessing. Trial eligibility depends on your gene and the stage of your disease, which is another reason to have genetic testing.
Treatment with us: a retinitis pigmentosa diagnosis is managed over many years, usually with a dedicated inherited-retinal-disease team. Our role is to review your scans, confirm what can be treated now (cataract, macular swelling), and operate when surgery helps. Retina care at Laser Istanbul Clinic is led by Doç. Dr. Muhammet Derda Özer (Doç. = Associate Professor), and Op. Dr. Aysan Bayram also treats retinal disease and cataract; Prof. Dr. Ahmet Satıcı performs cataract surgery, including premium lens options where suitable.
When to see a doctor about retinitis pigmentosa
Book an eye examination soon if you notice:
- difficulty seeing in dim light or adjusting to the dark, especially in a child or teenager
- missing objects at the side, bumping into things, or a feeling of looking through a tube
- a family member with retinitis pigmentosa or another inherited retinal disease
- hearing loss together with vision problems (possible Usher syndrome)
- if you already have RP: new central blur, distortion or a faster change than before
Get urgent same-day care for:
- a sudden drop in vision, a curtain across the vision, or a shower of new floaters and flashes. These are not typical of RP and can signal a retinal tear or detachment.
If you already have a diagnosis and want another opinion on cataract, macular swelling or your treatment options, you can send your scans for review.
Frequently asked questions
Retinitis pigmentosa is inherited in an autosomal recessive, autosomal dominant or X-linked pattern, and rarely a digenic one. Each child of two carrier parents has a 25% chance of recessive RP; each child of a parent with dominant RP has a 50% chance. Many people have no known relatives with RP, so absence of a family history does not rule it out.
It can be either, and X-linked too. In several large reviews the recessive forms make up around half or more of cases (50–60% in one 2026 review), but dominant RP is common and some patient-information sites call it the most frequent. Only genetic testing of the affected person tells you which pattern your family has.
More than 100 genes can. The best-known are RHO (dominant), USH2A (recessive) and RPGR (X-linked). A genetic test finds the gene in roughly 40–75% of people with inherited retinal disease, so a negative result does not exclude RP.
No cure exists for most forms. The one approved gene therapy, Luxturna, is for people with two faulty copies of the RPE65 gene. Other gene, cell and optogenetic therapies are in clinical trials. Meanwhile cataract and macular swelling can be treated, and low-vision support helps.
No one can give a date. Several late-stage trials are running in 2026, but which forms will benefit, and when treatments might be approved, is not known. Genetic testing now keeps you eligible for trials as they open.
It varies widely. Many people keep useful central vision for decades while the side vision narrows; X-linked forms tend to progress faster and dominant forms more slowly. In a study of about 1,000 patients aged 45 and over, only 0.5% were completely blind in both eyes.
Only one: voretigene neparvovec (Luxturna), approved in December 2017 for confirmed biallelic RPE65 mutation-associated retinal dystrophy. It does not apply to other RP genes. Late-stage trials of other gene therapies are under way, so approvals may change.
Complete blindness is uncommon. Many patients keep some sight, but many become legally blind in adulthood because of the narrow field. Course and speed differ by gene and individual.
Evidence is mixed. EyeWiki describes 15,000 IU/day of vitamin A palmitate as slowing functional decline in adults, whereas the American Academy of Ophthalmology says it is not currently recommended. High doses can be harmful, so only take it on a retina specialist's advice.
Sources for the facts on this page
- American Academy of Ophthalmology. What Is Retinitis Pigmentosa? https://www.aao.org/eye-health/diseases/what-is-retinitis-pigmentosa
- EyeWiki (AAO). Retinitis Pigmentosa. https://eyewiki.org/Retinitis_Pigmentosa
- MedlinePlus Genetics (US National Library of Medicine). Retinitis pigmentosa. https://medlineplus.gov/genetics/condition/retinitis-pigmentosa/
- Hamel C. Retinitis pigmentosa. Orphanet Journal of Rare Diseases 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC1621055/
- Barthelemy N, Barrett S, Lee W, Sengillo JD. Atypical retinitis pigmentosa associated with EYS variants (2026). https://pmc.ncbi.nlm.nih.gov/articles/PMC13091933/
- Wong AXJ, Chua Z, Guo J, et al. The Trajectory of Gene Discovery in Retinitis Pigmentosa (2026). https://pmc.ncbi.nlm.nih.gov/articles/PMC13512129/
- Foundation Fighting Blindness. Retinitis Pigmentosa. https://www.fightingblindness.org/diseases/retinitis-pigmentosa
- US FDA. LUXTURNA (voretigene neparvovec-rzyl). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna
- ClinicalTrials.gov. NCT04671433 (AAV5-RPGR phase 3). https://clinicaltrials.gov/study/NCT04671433
- ClinicalTrials.gov. NCT04850118 (AGTC-501 phase 2/3). https://clinicaltrials.gov/study/NCT04850118
- ClinicalTrials.gov. NCT06388200 (OCU400 phase 3). https://clinicaltrials.gov/study/NCT06388200
- ClinicalTrials.gov. NCT04945772 (MCO-010 phase 2, RESTORE). https://clinicaltrials.gov/study/NCT04945772
Diagnosed with retinitis pigmentosa, or worried about it in your family?
Send us your scans, visual field results or genetic report. Doç. Dr. Muhammet Derda Özer, our retina specialist, will review them and tell you what can be treated now, with no obligation.
3 eye surgeons
Your case is reviewed by a named surgeon, not a salesperson. Reply within {{response time}}.
Prof. Dr. Ahmet Satıcı
Doç. Dr. Muhammet Derda Özer
Op. Dr. Aysan Bayram